Skip to Content
  • Tetraphase and Their Troubles

    I wanted to provide an update of sorts to a piece from a few years back. This was the lawsuit brought by Mark Charest against Harvard et al. over royalties rela… Read More
  • More Rough Alzheimer’s News

    Man, Alzheimer’s. That’s my reaction to yesterday’s news in the field. Merck started things off with news of their last-ditch attempt to see i… Read More
  • Pay Your Money and Hold Your Breath

    In another example of the white-knuckle here-we-go nature of the drug business, Bristol-Myers Squibb announced this morning that they’re doing a huge deal… Read More
  • Bristol-Myers Squibb Sows Confusion

    Yesterday was a weird day for Bristol-Myers Squibb. The company announced the results of a highly anticipated clinical trial, one combining Opdivo (nivolumab) a… Read More
  • A New Look at Clinical Success Rates

    Andrew Lo of MIT and his co-workers have published a really interesting paper on clinical trial probability-of-success numbers. It appears to be the largest suc… Read More
  • The Landscape of Kinase Inhibitors

    I’ve been meaning to link to this article, which is the best overview I know of for kinase inhibitors. The authors (a large multicenter team led out of Mu… Read More
  • When Small Trials Convince

    This is a good piece by Bruce Booth in Forbes, and it points out something that’s changing in the biopharma landscape. Readers will have noticed over the… Read More
  • Silicon Stays in the Shadows

    I like this review, but I’ve seen it before. Well, not this exact manuscript, but every few years it seems there’s another one with a similar title… Read More
Page 1 of 4712345...102030...Last »